Advertisement

Topics

Big success and even bigger failure for Daiichi Sankyo's experimental therapy

06:54 EDT 3 Jul 2017 | Pharmafile

Daiichi Sankyo has been hit with mixed news this week regarding its experimental therapy mirogabalin. The drug posted trial success in treating patients with post-herpetic neuralgia by hitting its primary endpoint, yet failed to hit its target in a trial focused on fibromyalgia.

During the first trial in post-herpetic neuralgia examined 765 participants in Asia, mirogabalin showed its efficacy by producing a statistically significant reduction in the weekly average daily pain score from baseline to week 14 of the study.

read more

Original Article: Big success and even bigger failure for Daiichi Sankyo's experimental therapy

NEXT ARTICLE

More From BioPortfolio on "Big success and even bigger failure for Daiichi Sankyo's experimental therapy"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Pharmacy
Pharmacy is the science and technique of preparing as well as dispensing drugs and medicines. It is a health profession that links health sciences with chemical sciences and aims to ensure the safe and effective use of pharmaceutical drugs. The scope of...

Rheumatology
Arthritis Fibromyalgia Gout Lupus Rheumatic Rheumatology is the medical specialty concerned with the diagnosis and management of disease involving joints, tendons, muscles, ligaments and associated structures (Oxford Medical Diction...